Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

华盛顿大学参与者参与和癌症基因组测序中心 (WU-PE-CGS)

• 批准号: 10294012
• 负责人: GRAHAM A. COLDITZ
• 金额: $ 354.37万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10294012
• 关键词: Address; Advocacy; Aftercare; Age; CLIA certified; Cancer Patient; Cancer Survivor; Capital; Characteristics; Cholangiocarcinoma; Colorectal Cancer; Communication; Communities; Complex; Development; Disadvantaged; Discipline; Ensure; Environment; Evaluation Research; Family; Fostering; Genomics; Goals; Health Benefit; Health system; Investments; Knowledge; Lead; Leadership; Malignant Neoplasms; Methodology; Multiple Myeloma; Participant; Patient advocacy; Patients; Population; Positioning Attribute; Provider; Research; Research Personnel; Resources; Rural Population; Science; Technology; Testing; Underserved Population; Universities; Vision; Washington; anticancer research; cancer genomics; cancer health disparity; career; evidence base; follow-up; genome sequencing; improved; innovation; interdisciplinary collaboration; member; outreach; patient engagement; patient oriented; patient population; rare cancer; recruit; success; synergism; tumor

PROJECT SUMMARY Vision. Participant engagement and sequencing research from the Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge, methodology, and characterization of understudied cancer populations, leading to optimal approaches to participant engagement, outreach, and communication in genomic characterization studies. Goal. The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research. Our focus is on rare and understudied cancer populations with significant disparities including cholangiocarcinoma, multiple myeloma, and colorectal cancer under age 50. Participant engagement strategies are most effective when they are adapted and implemented in real-world settings in partnership with community and patient advocacy stakeholders. Setting. Our Center will be housed in an exceptional environment that fosters transdisciplinary collaboration, catalyzes new ideas in patient engagement, and ensures support for patient engagement and genome sequencing that finds solutions for complex recruitment and engagement challenges in real-world settings with underrepresented patient populations. Significant matching contributions from Washington University will allow us to quickly and strategically invest in ideas. Aims. The specific aims of the Center are to: (1) Advance the field of participant engagement to study cancer disparities and rare cancers by conducting innovative and impactful direct stakeholder engagement with continuous evaluation and research; (2) Expand an exceptional, diverse team of investigators, patients, and advocacy stakeholders; (3) Address cancer disparities by understanding barriers to and improving the ability for disadvantaged and understudied populations to encounter, use, and benefit from genomic sequencing and analysis; (4) Organize and integrate Center units to facilitate transdisciplinary, team science within our Center and across the PE-CGS Network. Innovations and impact. The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer disparities and genomic research across the cancer continuum. We will be particularly innovative and allow for a significant return on the scientific investment in several ways. First, our Center has distinctive features that include a combined focus on cancer disparities, the application of strategies to increase participant engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise. Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied cancers. Third, we engage investigators from different disciplines and invest in the development of early career scholars. Fourth, we will strategically and creatively disseminate products in ways that will benefit researchers, practitioners, and community members. Fifth, we will partner with exceptional patient-centered and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results. Input from these groups, patients, and their families is a key strength that will leverage our track record of stakeholder-engaged research. And finally, we have developed a focused strategy for collective integration of our units. These synergies will allow our Center to become a national resource for optimal approaches to participant engagement, outreach, and communication in genomic characterization studies and other studies as technologies advance that will accelerate progress for both the scientific community, patients and their communities. In summary, we are uniquely situated to advance a network of participant engagement and sequencing researchers, integrate research with patients and their stakeholders, build intellectual capital, and significantly enhance the capacity for participant engagement and genomic characterization studies. This Center will ultimately benefit health systems, providers, and people with rare cancers and lead to a reduction in cancer disparities.

项目摘要 想象。参与者参与和对华盛顿大学参与者的测序研究 参与和癌症基因组测序中心（WU-PE-CGS）将填补知识的关键空白， 方法论和研究不足的癌症种群的表征，导致最佳方法 参与者的参与，外展和基因组表征研究中的沟通。 目标。 Wu-Pe-CGS的总体目标是直接建立一个严格的科学证据基础 癌症患者和治疗后癌症幸存者的参与作为癌症研究的参与者。我们的 重点是稀有和研究的癌症种群，包括胆管癌，包括胆管癌， 多发性骨髓瘤和50岁以下的大肠癌。参与者参与策略最有效 当它们在现实环境中与社区和患者合作进行改编和实施时 倡导利益相关者。 环境。我们的中心将安置在培养跨学科合作的特殊环境中， 催化患者参与方面的新想法，并确保支持患者参与和基因组 在现实世界中找到复杂招聘和参与挑战的解决方案的测序 代表性不足的患者人群。华盛顿大学的重大匹配贡献将允许 我们要快速，战略性地投资思想。 目标。该中心的具体目的是：（1）推进参与者参与的领域来研究癌症 通过进行创新和有影响力的直接利益相关者参与与差异和罕见的癌症 持续评估和研究； （2）扩大一个杰出的，多样化的调查员，患者和 倡导利益相关者； （3）通过了解和提高能力的障碍来解决癌症差异 供弱势和研究的人群遇到，使用和受益于基因组测序和受益 分析; （4）组织和集成中心单位，以促进我们中心内的跨学科团队科学 以及跨PE-CGS网络。 创新和影响。 Wu-Pe-CGS以癌症的长期领导能力的长期记录为基础 癌症连续性的差异和基因组研究。我们将特别创新，并允许 科学投资的重大回报以多种方式回报。首先，我们的中心具有独特的功能 包括对癌症差异的综合关注，以及增加参与者的策略 参与研究，生物循环收购的成功以及卓越的基因组测序专业知识。 其次，我们组建了一个多样化的世界一流团队，与多个稀有和研究 癌症。第三，我们与来自不同学科的调查人员互动，并投资于早期的发展 职业学者。第四，我们将以有益的方式进行战略性和创造性传播产品 研究人员，从业者和社区成员。第五，我们将与以患者为中心的杰出合作 和广泛的倡导团体吸引患者，优化招聘并无缝返回结果。 这些群体，患者及其家人的投入是一个关键优势，它将利用我们的往绩记录 利益相关者参与研究。最后，我们制定了一种集体集成的集中策略 我们的单位。这些协同作用将使我们的中心成为最佳方法的国家资源 基因组表征研究和其他研究的参与者参与，外展和沟通 随着技术的发展，科学界，患者及其的进步将加速 社区。 总而言之，我们唯一的位置可以推进参与者参与和测序网络 研究人员，将研究与患者及其利益相关者整合，建立智力资本，并显着 增强参与者参与和基因组表征研究的能力。这个中心会 最终使卫生系统，提供者和患有罕见癌症的人受益，并导致癌症的减少 差异。